鳖甲煎丸对肝纤维化大鼠作用机制研究  

Effect and mechanism of Biejiajianwan on hepatic fibrosis in rats

作　　者：文彬 贺松其[2] 庞杰[2] 贾文燕[2] 孙海涛[2] 

机构地区：[1]解放军第四五八医院中医科,广东广州510602 [2]南方医科大学中医药学院,广东广州510515

出　　处：《中国中西医结合消化杂志》2013年第11期572-575,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：广东省中医药局基金资助课题(No:1060126)

摘　　要：[目的]探讨鳖甲煎丸抗肝纤维化的作用机制。[方法]采用复合因素建立肝纤维化大鼠模型。将大鼠随机分为正常组、模型组、秋水仙碱组、鳖甲煎丸高剂量组、鳖甲煎丸等剂量组。秋水仙碱组[0.11mg/(kg·d)]、鳖甲煎丸高剂量组[2.2g/(kg·d]及鳖甲煎丸等剂量组[1.1g/(kg·d]分别予以相应药物灌胃,模型组及正常组给予等剂量的0.9%氯化钠灌胃,共6周。采用比色法检测血清丙氨酸氨基转移酶,天冬氨酸转氨酶(ALT、AST)水平,苏木精-伊红染色观察肝组织病理学变化及肝纤维化程度,免疫组化方法检测肝组织瘦素、瘦素受体表达水平。[结果]鳖甲煎丸能降低大鼠血清ALT、AST水平,减轻肝脏炎症及纤维化程度(均P<0.01);抑制模型大鼠肝组织瘦素及瘦素受体的表达(P<0.01)。[结论]鳖甲煎丸能有效减轻模型大鼠肝纤维化的病理程度。其作用机制可能与降低大鼠血清ALT、AST水平,抑制大鼠肝组织瘦素及瘦素受体的表达密切相关。[Objective]To investigate the mechanism of Biejiajianwan in treating hepatic fibrosis.[Methods]Rat models of liver fibrosis were established based on multiple factors and then randomly divided into 5 groups：normal control,model group,colchicines group [0.11mg/（kg · d）],high dose of Biejiajianwan group [2.2g/（kg · d）] and equal dose of Biejiajianwan group [1.1g/（kg · d）].Rats in treatment groups were given relevant drugs with colchicines,high dose and equal dose of Biejiajianwan,while the same dose of normal saline was given to rats in model group and normal control for 6 weeks.Then ALT and AST levels were detected by colorimetry.Hepatic pathological changes and degree of liver fibrosis were observed by HE-staining.The expression of leptin and its receptor were determined by IHCA.[[Results]Biejiajianwan lowered serum level of ALT and AST,depressed the degree of liver inflammation and fibrosis（both P ＜0.01）and inhibited the expression of Leptin,OB-Rb in hepatic tissue of model rats（P＜0.01）.[Conclusion] Biejiajianwan can depress the pathological degree of liver fibrosis of rats.The mechanism may be closely related with depressing the degree of ALT and AST in serum,inhibiting the expression of Leptin and OB-Rb in hepatic tissue of rats.

关 键 词：鳖甲煎丸 肝纤维化 瘦素 瘦素受体 

分 类 号：R289.5[医药卫生—方剂学] R575.2[医药卫生—中药学]